TOKYO – SoftBank Group announced Thursday that it has begun operating a coronavirus testing facility on the outskirts of Tokyo’s local governments and businesses, Japan’s largest personal sector testing operation.
The verification center is the internal Kohnodai Hospital, the National Center for Health and Global Medicine, in Chiba Prefecture, east of the capital, and is controlled through a newly created subsidiary of SoftBank, the Coronavirus Inspection Center. SoftBank said it has a capacity of 4,000 checks consistent with the day and aims to accumulate up to 10,000 checks per day until November.
The facility will perform saliva-based polymerase reactions at the request of local governments and personal enterprises. Test kits will be sent to employees, who will collect saliva and send it to the SoftBank center.
The medium can report effects as temporarily as two hours, according to SoftBank. Each test, shipment and packaging costs 2,000 yen ($19).
SoftBank’s initiative only targets other asymptomatic people and prevents them from spreading the coronavirus. SoftBank said the facility was designed under the direction of the National Center for Health and Global Medicine, a study firm under the Department of Health.
SoftBank has in the past conducted antibody testing on 44,000 workers and affiliated companies in the group. The company opens up its testing capability to third parties.
Masayoshi Son, founder and president of SoftBank, has been a strong advocate for the widespread personal sector as a way to deal with the spread of COVID-19.
Japan’s overall coronavirus capacity is approximately 68,200 s consistent with the day, according to the Ministry of Health.
Subscribe to our newsletters to get our stories right in your inbox.
You want an Array subscription. .